April 16, 2025 - 02:52

It’s getting hard to tell which is more pathetic: this year’s crop of mayoral candidates, or the city’s system for electing one of them. As the election season heats up, the shortcomings of New York City's Campaign Finance Board have come under intense scrutiny. The Board, which is supposed to provide a fair and transparent financial landscape for candidates, has drawn criticism for its inconsistent decisions and lack of support for prominent figures like Mayor Eric Adams and former Governor Andrew Cuomo.
Candidates are finding themselves navigating a confusing and often frustrating financial framework that seems to favor some while sidelining others. This has led to questions about the integrity of the electoral process and whether the current system truly serves the interests of the voters. As the mayoral race continues, the discontent surrounding the campaign finance structure is likely to overshadow the candidates themselves, raising concerns about the future of governance in the city. Voters are left wondering if they can trust the system to deliver a fair election.
June 8, 2026 - 22:27
What history tells us about Marvell's upcoming S&P 500 inclusionMarvell Technology shares have been climbing sharply after the announcement that the company will join the S&P 500 index on June 22. Investors are betting that the move will bring fresh demand from...
June 8, 2026 - 04:51
Is PDD Holdings Inc. (PDD) A Good Stock To Buy Now?A recent discussion on a value investing forum laid out a bullish case for PDD Holdings Inc., the parent company of e-commerce platforms Temu and Pinduoduo. As of late May, shares were trading near...
June 7, 2026 - 03:13
Apple Stock: Buy, Sell, or Hold?Apple`s stock is trading close to an all-time high, and a series of potential catalysts could sustain the upward momentum. The company continues to benefit from strong demand for its latest iPhone...
June 6, 2026 - 22:38
Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are MissingEli Lilly is making a serious push into the vaccine business. The pharmaceutical giant announced a trio of acquisitions totaling $3.8 billion, aimed at building a new division focused on infectious...